MC4R Agonist(s) for Rare Obesity

About Palatin Technologies

Palatin Technologies is a clinical-stage biopharmaceutical company leveraging its proprietary Melanocortin Receptor Platform to develop targeted therapeutics for inflammatory, autoimmune, and metabolic conditions. Its lead programs focus on MC4R agonists for obesity, particularly rare neuroendocrine disorders like hypothalamic obesity and Prader-Willi syndrome, representing a paradigm shift from broad immunosuppression to targeted resolution. Recent achievements include a strategic collaboration with Boehringer Ingelheim in retinal diseases and positive preclinical data for an oral obesity candidate, though the company operates as a pre-revenue entity navigating clinical development and financing risks.

About Palatin Technologies

Palatin Technologies is a clinical-stage biopharmaceutical company leveraging its proprietary Melanocortin Receptor Platform to develop targeted therapeutics for inflammatory, autoimmune, and metabolic conditions. Its lead programs focus on MC4R agonists for obesity, particularly rare neuroendocrine disorders like hypothalamic obesity and Prader-Willi syndrome, representing a paradigm shift from broad immunosuppression to targeted resolution. Recent achievements include a strategic collaboration with Boehringer Ingelheim in retinal diseases and positive preclinical data for an oral obesity candidate, though the company operates as a pre-revenue entity navigating clinical development and financing risks.

Therapeutic Areas